These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 36195687)

  • 1. Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial.
    Feigin A; Evans EE; Fisher TL; Leonard JE; Smith ES; Reader A; Mishra V; Manber R; Walters KA; Kowarski L; Oakes D; Siemers E; Kieburtz KD; Zauderer M;
    Nat Med; 2024 Feb; 30(2):606. PubMed ID: 36195687
    [No Abstract]   [Full Text] [Related]  

  • 2. Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial.
    Feigin A; Evans EE; Fisher TL; Leonard JE; Smith ES; Reader A; Mishra V; Manber R; Walters KA; Kowarski L; Oakes D; Siemers E; Kieburtz KD; Zauderer M;
    Nat Med; 2022 Oct; 28(10):2183-2193. PubMed ID: 35941373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial.
    Huntington Study Group Reach2HD Investigators
    Lancet Neurol; 2015 Jan; 14(1):39-47. PubMed ID: 25467848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial.
    de Yebenes JG; Landwehrmeyer B; Squitieri F; Reilmann R; Rosser A; Barker RA; Saft C; Magnet MK; Sword A; Rembratt A; Tedroff J;
    Lancet Neurol; 2011 Dec; 10(12):1049-57. PubMed ID: 22071279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial.
    Furr Stimming E; Claassen DO; Kayson E; Goldstein J; Mehanna R; Zhang H; Liang GS; Haubenberger D;
    Lancet Neurol; 2023 Jun; 22(6):494-504. PubMed ID: 37210099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study.
    Reilmann R; Anderson KE; Feigin A; Tabrizi SJ; Leavitt BR; Stout JC; Piccini P; Schubert R; Loupe P; Wickenberg A; Borowsky B; Rynkowski G; Volkinshtein R; Li T; Savola JM; Hayden M; Gordon MF;
    Lancet Neurol; 2024 Mar; 23(3):243-255. PubMed ID: 38280392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation and preclinical characterization of an antibody specific for SEMA4D.
    Fisher TL; Reilly CA; Winter LA; Pandina T; Jonason A; Scrivens M; Balch L; Bussler H; Torno S; Seils J; Mueller L; Huang H; Klimatcheva E; Howell A; Kirk R; Evans E; Paris M; Leonard JE; Smith ES; Zauderer M
    MAbs; 2016; 8(1):150-62. PubMed ID: 26431358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Huntington's Disease Clinical Trials Corner: November 2022.
    Estevez-Fraga C; Tabrizi SJ; Wild EJ
    J Huntingtons Dis; 2022; 11(4):351-367. PubMed ID: 36463457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, placebo-controlled trial evaluating cysteamine in Huntington's disease.
    Verny C; Bachoud-Lévi AC; Durr A; Goizet C; Azulay JP; Simonin C; Tranchant C; Calvas F; Krystkowiak P; Charles P; Youssov K; Scherer C; Prundean A; Olivier A; Reynier P; Saudou F; Maison P; Allain P; von Studnitz E; Bonneau D;
    Mov Disord; 2017 Jun; 32(6):932-936. PubMed ID: 28436572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease.
    Huntington Study Group HART Investigators
    Mov Disord; 2013 Sep; 28(10):1407-15. PubMed ID: 23450660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tetrabenazine Versus Deutetrabenazine for Huntington's Disease: Twins or Distant Cousins?
    Rodrigues FB; Duarte GS; Costa J; Ferreira JJ; Wild EJ
    Mov Disord Clin Pract; 2017; 4(4):582-585. PubMed ID: 28920068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ethyl-eicosapentaenoic acid treatment in Huntington's disease: A placebo-controlled clinical trial.
    Ferreira JJ; Rosser A; Craufurd D; Squitieri F; Mallard N; Landwehrmeyer B
    Mov Disord; 2015 Sep; 30(10):1426-9. PubMed ID: 26175332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical Trial.
    Brownstein MJ; Simon NG; Long JD; Yankey J; Maibach HT; Cudkowicz M; Coffey C; Conwit RA; Lungu C; Anderson KE; Hersch SM; Ecklund DJ; Damiano EM; Itzkowitz DE; Lu S; Chase MK; Shefner JM; McGarry A; Thornell B; Gladden C; Costigan M; O'Suilleabhain P; Marshall FJ; Chesire AM; Deritis P; Adams JL; Hedera P; Lowen K; Rosas HD; Hiller AL; Quinn J; Keith K; Duker AP; Gruenwald C; Molloy A; Jacob C; Factor S; Sperin E; Bega D; Brown ZR; Seeberger LC; Sung VW; Benge M; Kostyk SK; Daley AM; Perlman S; Suski V; Conlon P; Barrett MJ; Lowenhaupt S; Quigg M; Perlmutter JS; Wright BA; Most E; Schwartz GJ; Lamb J; Chuang RS; Singer C; Marder K; Moran JA; Singleton JR; Zorn M; Wall PV; Dubinsky RM; Gray C; Drazinic C
    J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33207828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Placebo effect characteristics observed in a single, international, longitudinal study in Huntington's disease.
    Cubo E; González M; del Puerto I; de Yébenes JG; Arconada OF; Gabriel y Galán JM;
    Mov Disord; 2012 Mar; 27(3):439-42. PubMed ID: 22162184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study.
    Reilmann R; McGarry A; Grachev ID; Savola JM; Borowsky B; Eyal E; Gross N; Langbehn D; Schubert R; Wickenberg AT; Papapetropoulos S; Hayden M; Squitieri F; Kieburtz K; Landwehrmeyer GB; ;
    Lancet Neurol; 2019 Feb; 18(2):165-176. PubMed ID: 30563778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pepinemab (Anti-SEMA4D) in Combination with Ipilimumab or Nivolumab for Patients with Resectable Pancreatic and Colorectal Cancer.
    Rossi AJ; Khan TM; Hong H; Lesinski GB; Wu C; Hernandez JM
    Ann Surg Oncol; 2021 Aug; 28(8):4098-4099. PubMed ID: 33987757
    [No Abstract]   [Full Text] [Related]  

  • 17. A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease.
    López-Sendón Moreno JL; García Caldentey J; Trigo Cubillo P; Ruiz Romero C; García Ribas G; Alonso Arias MA; García de Yébenes MJ; Tolón RM; Galve-Roperh I; Sagredo O; Valdeolivas S; Resel E; Ortega-Gutierrez S; García-Bermejo ML; Fernández Ruiz J; Guzmán M; García de Yébenes Prous J
    J Neurol; 2016 Jul; 263(7):1390-400. PubMed ID: 27159993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, placebo-controlled trial of AFQ056 for the treatment of chorea in Huntington's disease.
    Reilmann R; Rouzade-Dominguez ML; Saft C; Süssmuth SD; Priller J; Rosser A; Rickards H; Schöls L; Pezous N; Gasparini F; Johns D; Landwehrmeyer GB; Gomez-Mancilla B
    Mov Disord; 2015 Mar; 30(3):427-31. PubMed ID: 25689146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Riluzole in Huntington's disease: a 3-year, randomized controlled study.
    Landwehrmeyer GB; Dubois B; de Yébenes JG; Kremer B; Gaus W; Kraus PH; Przuntek H; Dib M; Doble A; Fischer W; Ludolph AC;
    Ann Neurol; 2007 Sep; 62(3):262-72. PubMed ID: 17702031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From open to large-scale randomized cell transplantation trials in Huntington's disease: Lessons from the multicentric intracerebral grafting in Huntington's disease trial (MIG-HD) and previous pilot studies.
    Bachoud-Lévi AC
    Prog Brain Res; 2017; 230():227-261. PubMed ID: 28552231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.